Disc Medicine, Inc.
StreetZero Signal 64
About Disc Medicine, Inc.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. The company is building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. It is headquartered in Watertown, Massachusetts.
LATEST FUNDINGRule 144
$2.7M
Announced 2026-10-21
TOTAL RAISED$140M
IN THE NEWS
- 🔗 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants - Disc Medicine Inc.
- 🔗 Disc Medicine - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Disc Medicine - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
- 🔗 Disc Medicine Announces Pricing of Upsized $450 Million Public Offering | Quiver Quantitative
EMPLOYEES—
FOUNDED2017
HQWatertown, MA, United States
Industry
Public Equity (Nasdaq)
Tags
BiopharmaceuticalClinical-stageHematologic diseasesPublic
Key highlights
- Raised $140M total across 4 rounds since 2017.
- Completed post-IPO financing in Feb 2023 with 3 investors.
- Announced proposed $350M and upsized $450M public offerings in 2026.
- Focuses on heme biosynthesis and iron homeostasis pathways for hematologic diseases.
- 14 institutional investors have participated in its funding rounds.
Ask StreetZero about Disc Medicine, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (Nasdaq) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account